From mouse to man: Or what have we learned about cytokine-based anti-inflammatory therapies?

Shock

Volumn 11, Issue 3, 1999, Pages 224-225

  Tracey, Kevin J ^a   Abraham, Edward ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CLINICAL TRIAL; DISEASE MODEL; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; MORTALITY; MOUSE; REVIEW; SEPSIS;

ANIMALS; ANTIBODIES; CLINICAL TRIALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033087466     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/00024382-199903000-00012     Document Type: Note

References (9)

1. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment [editorial comment]. Crit Care Med 25:1095-1100, 1997. (Pubitemid 27310241)
2. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1127, 1994. (Pubitemid 24317633)
3. van Dullemen HS, van Deventer SJ, Hommes DW, Biji HA, Jansen J, Tytgat GN, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109(1): 129-135, 1995.
4. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TF III, Zentella A, Albert JD, Shires GT, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474, 1986. (Pubitemid 17181429)
5. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664, 1987. (Pubitemid 18005583)
6. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351:929-933, 1998. (Pubitemid 28138465)
7. Fisher CJ, Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697-1702, 1996. (Pubitemid 26193621)
8. Altman LK: First drug solely for Crohn's disease get panel's backing. New York Times. May 29, 1998.
9. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148:2724-2730, 1992.